Showing 3481-3490 of 4082 results for "".
- UW's Simpson Lab Awarded $590K to Study Hailey-Hailey Diseasehttps://practicaldermatology.com/news/uws-simpson-lab-awarded-590k-to-study-hailey-hailey-disease/2462172/The Simpson Lab at the University of Washington has been awarded a three-year $590K grant by the LEO Foundation for ongoing research in Hailey-Hailey disease (HHD). Funding from this award will support Simpson Lab personnel and provide supplies for research aimed at investigating how mu
- Take That, Melanoma! ATM Kinase Inhibitors May Stop Metastasishttps://practicaldermatology.com/news/take-that-melanona-atm-kinase-inhibitors-may-stop-metastasis/2462146/Ataxia telangiectasia mutated (ATM) kinase inhibition may target the metastatic capacity of melanoma cells, according to a research team led by Wolfgang Weninger and Shweta Tikoo from MedUni Vienna's Department of Dermatology. The results of the study, which appe
- AD Pipeline Watch: Rademikibart Maintains Efficacy Out to Week 52https://practicaldermatology.com/news/ad-pipeline-watch-rademikibart-maintains-efficacy-out-to-week-52/2462145/Connect Biopharma’s rademikibart continues to wow in patients with moderate-to-severe atopic dermatitis, according to topline results from the Stage 2 (maintenance period) of its China pivotal trial. Rademikibart is an inhibitory human monoclonal antibody against the IL-4Rα
- More Photos of Patients with Psoriasis Needed in Studieshttps://practicaldermatology.com/news/more-photos-of-patients-with-psoriasis-needed-in-studies/2462142/As the adage goes, "a picture is worth a thousand words," yet most researchers don't include photos of patients with psoriasis in scientific articles. This is the main finding from a new study out of the University of Gothenburg in Sweden and the University of Copenha
- Unmet Needs in Dermatology: NFX-179 Topical Gel May Shrink Cutaneous Neurofibromas in NF1 Patientshttps://practicaldermatology.com/news/unmet-needs-in-dermatology-nfx-179-topical-gel-may-shrink-cutaneous-neurofibromas-in-nf1-patients/2462134/NFX‑179 Gel produced a statistically significant improvement over vehicle in the shrinkage of cutaneous neurofibromas in people with neurofibromatosis type 1 (NF1), according to positive topline results from a Phase 2b clinical trial. Cutaneous neurofibromas (cNFs) appear in over 9
- ACR: TREMFYA Improves Pain, Physical Function and Fatigue in PsA Patients Through Six Monthshttps://practicaldermatology.com/news/acr-tremfya-improves-pain-physical-function-and-fatigue-in-psa-patients-through-six-months/2462121/Substantial numbers of people living with treatment-resistant active PsA who used TREMFYA (guselkumab) in real-world settings reported meaningful improvements in pain, physical function and fatigue through six months, according to new data from the CorEvitas Psoriatic Arthritis (PsA) and Spo
- In the Lab With Boston University Melanoma Researcher Deborah Langhttps://practicaldermatology.com/news/in-the-lab-with-boston-university-melanoma-researcher-deborah-lang-phd/2462120/Deborah Lang, PhD, associate professor of dermatology at Boston University Chobanian & Avedisian School of Medicine, received a two-year, $300,000 Discovery Boost Grant from the American Cancer Society (ACS) for her research project “Exploring roles for PAX3 in regulating gene expressio
- Study Validates Long-Term Safety of Delgocitinib Cream in Adults With Chronic Hand Eczemahttps://practicaldermatology.com/news/study-validates-long-term-safety-of-delgocitinib-cream-in-adults-chronic-hand-eczema/2462105/LEO Pharma’s Delgocitinib Cream was well-tolerated in adults with moderate to severe chronic hand eczema (CHE), according to results from the DELTA 3 Open-Label Extension Trial. What’s more, patients who entered the DELTA 3 trial after receiving delgocitinib cream
- UCSF's HS PROGRESS Aims to Shed Light on Hidradenitis Suppurativahttps://practicaldermatology.com/news/ucsfs-hs-progress-aims-to-shed-light-on-hidradenitis-suppurativa/2462092/University of California-San Francisco (UCSF) is leading HS PROGRESS (Hidradenitis Suppurativa [HS] Prospective Observational Registry and bioSpecimen repoSitory), a multicenter, longitudinal study that aims to comprehensively characterize HS from clinical and biological perspectives. <
- TREMFYA (Guselkumab) Improves PsO Symptoms Across All Skin Toneshttps://practicaldermatology.com/news/tremfya-guselkumab-improves-pso-symptoms-across-all-skin-tones/2462086/TREMFYA demonstrated significant skin clearance, rapid scalp psoriasis clearance and improvement in health-related quality of life outcomes in psoriasis patients across all skin tones, according to results from Cohort A of the VISIBLE trial. This study, which was presented at the